Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 991 matching trials from the live ClinicalTrials.gov search.
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
OPN-6602, Dexamethasone
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Stanford, California + 9 more
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Conditions
Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Interventions
Sirolimus Drug Coated Balloon, Drug eluting stents (DES)
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
24
States / cities
Gilbert, Arizona • Los Angeles, California • Clearwater, Florida + 19 more
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Interventions
Zilovertamab vedotin, Nemtabrutinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more
Conditions
Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Interventions
ibrutinib, everolimus, paclitaxel, docetaxel, cetuximab, pembrolizumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
Conditions
Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
Interventions
EMBLEM S-ICD System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Conditions
Spasticity
Interventions
SPARC0921, Placebo0921
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 50 more
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Conditions
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Interventions
FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin
Drug · Biological
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
107
States / cities
Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 65 more
Conditions
Esophageal Cancer
Interventions
Nivolumab, Docetaxel/Paclitaxel
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • Orlando, Florida + 4 more
Conditions
Tophaceous Gout
Interventions
Allopurinol, Dotinurad
Drug
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 89 more
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Conditions
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
Interventions
Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
14
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, irinotecan hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
406
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 273 more
Conditions
Bacteremia, Fungemia
Interventions
Not listed
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
4,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Conditions
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
1,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib 150 mg bid
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
31
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 27 more
Conditions
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more